Navigation Links
MGT Capital Investments, Inc. Provides Update on Recent Developments
Date:8/22/2011

dicsight has decided to close the Tokyo office as part of an overall program of expense reduction and corporate simplification.  
  • In addition to closing the Tokyo office, management of Medicsight has decided to close several other subsidiaries in Australia, China and the UAE citing the unjustifiably high legal, regulatory and accounting costs of maintaining such entities. However, in order to better exploit the recent U.S. Food and Drug Administration's approval of ColonCAD, the Company will open a U.S. subsidiary (Medicsight, Inc.) in New York.

  • The Board of Directors of Medicsight has also agreed to call a General Meeting of stockholders on September 14, 2011 to vote on whether to cancel its Ordinary Shares from trading on the AIM Exchange and to re-register as a private company.  Given that recent results have diminished the ability to raise new capital, along with the relatively large expense of maintaining a public listing, Medicsight's Board is recommending this course of action as in the best interest of Medicsight and all MDST stockholders.

  • On August 16, 2011 Peter Venton resigned from the Board of MGT. This action was taken to ensure that at least one Board member of MDST is independent of MGT.  In light of the announcement of the proposal to cancel the AIM quotation, it was considered impracticable to recruit any further independent directors for MDST at the current time.  However, should shareholders not pass the resolutions to effect the cancellation of the AIM quotation, the Board of Directors of MDST will take steps to supplement its current Board with an additional independent non-executive Director.

  • NYSE Amex LLC has halted trading in the common stock of MGT pending the restarting of trading of MDST shares on the AIM market
    '/>"/>

SOURCE MGT Capital Investments, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
3. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
4. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
5. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
6. BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available
7. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
8. Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million
9. Baxa Addresses Health-System Capital Shortage With New Programs for IntelliFlowRx(TM) and IntelliFill i.v.(R)
10. New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers
11. Accumetrics Announces $16.5M in New Capital Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Third Quarter 2007, HAYWARD, Calif., June 04, ... from a dose-escalating,Phase 1b clinical trial of ... with bortezomib (Velcade(R)), showing a,high degree of ... myeloma who had previously progressed following treatment,with ...
... NASDAQ: CRME TSX: COM, VANCOUVER and DEERFIELD, ... Corp. and its,co-development partner Astellas Pharma US, ... completed Phase 3 clinical,study, called ACT 2. ... of,the intravenous formulation of vernakalant hydrochloride,("vernakalant (iv)") ...
Cached Medicine Technology:Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 2Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 3Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 4Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 5Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 6Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6
(Date:12/26/2014)... 2014 Plugin and template developers from ... Plugin for Final Cut Pro X. , “TransPack Volume 5 ... to pull off an industry professional look” Said Christina Austin, ... on TransPack Volume 5, a new level of professionalism will ... of over 50 Final Cut Pro X transitions featuring organic ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... 2014 “Every three months the trends for ... sweetheart evening dress will be one of the hottest styles ... Yunx.co.uk says. Today, the company releases 26 A-line sweetheart evening ... 80% off. , “We are trying our best to ... our latest designs. Along with affordable prices, we provide discounted ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... been a considerable increase in the number of repeat cesarean ... 8-year study conducted between 1996 and 2003 survey has further ... unexplained reasons. ,According to National statistics, there has ... in women who have had a cesarean. Concomitantly, there has ...
... first step to retaining a good memory as we age is ... that they could control their memory are more likely to use ... ,The researchers analyzed the link between a sense of control ... and 83 years. The study participants were required to recall a ...
... pollution could be responsible for increase in cardiac and ... the recent issue of JAMA. , The ... disorders have been highlighted by numerous environment based studies. ... health is being perceived as a major public health ...
... of an association between aluminum salts contained in deodorants ... like cadmium and aluminum are believed to exert estrogen-like ... ,Under laboratory conditions, these salts have even ... cell lines, highlighting the carcinogenic potential of such compounds, ...
... increased over the last 10 years, a survey has found. ... ,A South Australian survey conducted between 1990 and 2003 ... from 7.3 percent in 1990 to 14.6 percent in 2003. ... people aged 55 and above. Overall the prevalence rate rose ...
... University of Illinois at Urbana-Champaign developed an innovative ... new drug and agricultural materials and delivery vehicles. ... engineering, chemistry and physics said that it was ... biofunctional capsules could be used in drug delivery, ...
Cached Medicine News:Health News:Want To Retain Your Memory? Believe That You Can Do So! 2Health News:Air Pollution Exposure Increases Risk Of Heart And Respiratory Disease 2Health News:Aluminum Salts In Underarm Deodorants Increase Risk Of Breast Cancer 2Health News:Medical Boon in the Form of a Biofriendly Capsule 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: